Bioverativ awarded a $100 million contract to the UK's Oxford BioMedica to develop lentiviral vectors for use in Bioverativ's hemophilia gene therapies. Oxford BioMedica will receive an upfront payment of $5 million and will be eligible for several milestone payments, with a potential value exceeding $100 million, as well as royalties on sales of Bioverativ's hemophilia therapies that are under development.
A round of Series A funding brought in approximately $19.9 million for Abac Therapeutics, which uses the PasNas platform in discovering antibiotics. Abac intends to use the proceeds to start clinical studies of its lead program, which targets multidrug-resistant Acinetobacter baumannii.
Biotech foods have met with extreme public resistance based on misinformation from sensationalist headlines and propaganda, despite overwhelming evidence to the contrary, and experts in the field fear that gene-edited products will meet a similar response. Science writer Michael Specter of the New Yorker says the best response is to simply keep countering erroneous beliefs with facts: "You have to fight misinformation and lies with the truth."
A team of researchers led by the University of Georgia found that the manipulation of a gene in poplar trees and switchgrass can improve plant growth and improves the efficiency with which they are converted to biofuel. Reducing the activity of the gene GAUT4 results in lower levels of pectin, which is responsible for resistance to deconstruction.
As part of its "Empowering Life" corporate branding campaign, Sanofi has redesigned and simplified its web presence, cutting the number of sites worldwide in half from 140 to 70. The more modern appearance is designed to help a range of users, including patients, investors, reporters and employees, find the information they want.
Drew Train, co-founder and president of the ad agency Oberland, says more assumptions are made about his generation -- millennials -- than any other demographic. Train and other millennials working in health care marketing explain 10 myths related to their generation, such as that they don't care about their health and that they don't trust physicians.
Customer service, satisfaction and loyalty have guided other industries for years, and hospitals could benefit from putting more focus on the customer as well, says Preston Gee, vice president of strategic marketing at Christus Health. Gee talks about what hospitals can learn from other industries about attracting and retaining customers.
A go-private sale to TPG Capital, valued at $737 million, was completed by Exactech, with all its issued and outstanding stock acquired by TPG. The sale stops the listing of Exactech's common stock on the Nasdaq exchange.
Becton Dickinson announced the closing of a $100 million deal to sell its soft tissue core needle biopsy devices and Aspira product line to South Jordan, Utah-based Merit Medical. The direct sales force and distribution partners of Merit will be in charge of selling the assets, which include the Temno biopsy system, Achieve programmable automatic biopsy system, Achieve programmable automatic biopsy system and Tru-Cut biopsy needles.
A round of financing pulled in $12 million for Israeli medical device company Perflow Medical, which makes solutions for the treatment of complex neurovascular disorders. The proceeds will be used for commercialization of its first product, the Stream Dynamic Neuro-Thrombectomy Net device, as well as to support development of new products and 510(k) submission.